Darmstadt, Germany (ots/PRNewswire) – · New analyses from Phase III JAVELIN
Bladder 100 study of BAVENCIO®* assess efficacy across subgroups,
patient-reported outcomes and exploratory biomarkers in advanced urothelial
cancer

· Overall efficacy data, and analyses of brain metastases and HRQoL for
tepotinib? from largest ongoing study in NSCLC harboring MET ex14 skipping

· Long-term follow-up data